Valuation : InspireMD

Market Cap 41.38M 35.51M 33.33M 30.44M 57.45M 3.95B 57.73M 394M 153M 1.99B 155M 152M 6.59B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 41.38M 35.51M 33.33M 30.44M 57.45M 3.95B 57.73M 394M 153M 1.99B 155M 152M 6.59B EV / Sales 2026 *
4.22x
EV / Sales 2027 * 2.06x
Free-Float
80.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 2019-12-31
Director of Finance/CFO 58 2025-06-24
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 2017-06-01
Director/Board Member 68 2013-02-06
Director/Board Member 62 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%+32.01% - - 41.38M
-0.44%+0.11%-16.55%+17.88% 126B
+0.14%+0.37%-22.28%-0.05% 12.24B
+0.86%-1.09%+92.26%+147.07% 10.65B
+2.13%-4.21%-51.63%-68.92% 4.21B
+0.57%+4.02%-22.01%+58.76% 2.77B
-0.24%+0.58%-33.23%-71.81% 1.79B
+1.12%-0.84%-23.32%-12.99% 1.66B
+0.47%-3.59%-36.96%-38.68% 1.59B
Average +0.10%-0.58%-14.22%+3.91% 20.17B
Weighted average by Cap. -0.21%-2.62%-11.27%+21.62%

Financials

2026 *2027 *
Net sales 9.8M 8.41M 7.89M 7.21M 13.61M 935M 13.67M 93.42M 36.21M 472M 36.79M 35.99M 1.56B 20.13M 17.28M 16.22M 14.81M 27.96M 1.92B 28.09M 192M 74.38M 969M 75.59M 73.95M 3.21B
Net income - -
Net Debt - -
Logo InspireMD
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-